Evogene Ltd., along with its subsidiaries, operates as a computational biology firm. Its core activity involves the discovery and advancement of products across diverse life-science sectors, such as human health and agriculture, primarily leveraging its proprietary Computational Predictive Biology (CPB) platform. This platform, built on deep biological insights, big data analytics, and artificial intelligence, is engineered to digitally identify and strategically guide the creation of life-science solutions derived from microbes, small molecules, and genetic components. The company's operations are structured into three primary divisions: Agriculture, Human Health, and Industrial Applications. Within the Agriculture division, Evogene works on seed traits, agricultural chemicals, and biological products aimed at improving plant yields, with efforts spanning critical crops like corn, soybean, wheat, rice, and cotton. The Industrial Applications segment focuses on enhancing castor bean seeds for use as a raw material in various industrial applications. Meanwhile, the Human Health segment is dedicated to uncovering and developing human microbiome-based treatments for conditions including immuno-oncology, gastrointestinal disorders, and antimicrobial-resistant infections. Beyond these core areas, Evogene also delivers medical cannabis products. The company maintains a global presence, conducting operations in the United States, Israel, Brazil, and other international markets. It has forged key partnerships and licensing agreements with leading agricultural enterprises, such as BASF SE, Corteva, and Bayer. Additionally, its subsidiary, Canonic Ltd., collaborates with Cannbit Ltd. on the development of innovative medical cannabis offerings. Established in 1999, Evogene Ltd. is based in Rehovot, Israel.
Previous close
$0.5379
−$0.0071 · -1.30%
Regular session · ET · Market data may be delayed.
Evogene Ltd., along with its subsidiaries, operates as a computational biology firm. Its core activity involves the discovery and advancement of products across diverse life-science sectors, such as human health and agriculture, primarily leveraging its proprietary Computational Predictive Biology (CPB) platform. This platform, built on deep biological insights, big data analytics, and artificial intelligence, is engineered to digitally identify and strategically guide the creation of life-science solutions derived from microbes, small molecules, and genetic components. The company's operations are structured into three primary divisions: Agriculture, Human Health, and Industrial Applications. Within the Agriculture division, Evogene works on seed traits, agricultural chemicals, and biological products aimed at improving plant yields, with efforts spanning critical crops like corn, soybean, wheat, rice, and cotton. The Industrial Applications segment focuses on enhancing castor bean seeds for use as a raw material in various industrial applications. Meanwhile, the Human Health segment is dedicated to uncovering and developing human microbiome-based treatments for conditions including immuno-oncology, gastrointestinal disorders, and antimicrobial-resistant infections. Beyond these core areas, Evogene also delivers medical cannabis products. The company maintains a global presence, conducting operations in the United States, Israel, Brazil, and other international markets. It has forged key partnerships and licensing agreements with leading agricultural enterprises, such as BASF SE, Corteva, and Bayer. Additionally, its subsidiary, Canonic Ltd., collaborates with Cannbit Ltd. on the development of innovative medical cannabis offerings. Established in 1999, Evogene Ltd. is based in Rehovot, Israel.
Day range
Current $0.5379
52-week range
Current $0.5379
Regular session · ET · Market data may be delayed.
AI-powered factor overview
GoAI Score
Sell
Trim exposure — unfavorable risk-reward
Valuation
29
Expensive
Sentiment
60
Mixed
Risk
69
High Risk
Momentum
20
Strong Down
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Evogene Ltd., along with its subsidiaries, operates as a computational biology firm. Its core activity involves the discovery and advancement of products across diverse life-science sectors, such as human health and agriculture, primarily leveraging its proprietary Computational Predictive Biology (CPB) platform. This platform, built on deep biological insights, big data analytics, and artificial intelligence, is engineered to digitally identify and strategically guide the creation of life-science solutions derived from microbes, small molecules, and genetic components. The company's operations are structured into three primary divisions: Agriculture, Human Health, and Industrial Applications. Within the Agriculture division, Evogene works on seed traits, agricultural chemicals, and biological products aimed at improving plant yields, with efforts spanning critical crops like corn, soybean, wheat, rice, and cotton. The Industrial Applications segment focuses on enhancing castor bean seeds for use as a raw material in various industrial applications. Meanwhile, the Human Health segment is dedicated to uncovering and developing human microbiome-based treatments for conditions including immuno-oncology, gastrointestinal disorders, and antimicrobial-resistant infections. Beyond these core areas, Evogene also delivers medical cannabis products. The company maintains a global presence, conducting operations in the United States, Israel, Brazil, and other international markets. It has forged key partnerships and licensing agreements with leading agricultural enterprises, such as BASF SE, Corteva, and Bayer. Additionally, its subsidiary, Canonic Ltd., collaborates with Cannbit Ltd. on the development of innovative medical cannabis offerings. Established in 1999, Evogene Ltd. is based in Rehovot, Israel.
Day range
Current $0.5379
52-week range
Current $0.5379
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 3.85M USD | 5.58M USD | 2.98M USD | 1.68M USD | 930K USD |
| Cost of goods sold | 4.09M USD | 2.38M USD | 1.49M USD | 909K USD | 767K USD |
| Gross profit | −241K USD | 3.2M USD | 1.49M USD | 766K USD | 163K USD |
| Research and development | 7.99M USD | 12.51M USD | 16.2M USD | 20.79M USD | 21.13M USD |
| Selling, general, and administrative | 5.76M USD | 8.98M USD | 7.53M USD | 10.42M USD | 9.99M USD |
| Operating expenses | 13.79M USD | 22M USD | 23.72M USD | 27.71M USD | 31.12M USD |
| Interest income | 2.47M USD | 957K USD | 1.25M USD | 182K USD | 291K USD |
| Interest expense | 1.89M USD | 124K USD | 171K USD | 241K USD | 403K USD |
| Depreciation and amortization | 1.14M USD | 1.38M USD | 1.3M USD | 2.58M USD | 2.23M USD |
| Operating income | −14.03M USD | −18.8M USD | −22.23M USD | −26.94M USD | −30.95M USD |
| Net income | −8.49M USD | −16.49M USD | −23.88M USD | −26.64M USD | −27.79M USD |
Company facts updated Sep 6, 2026.
Recent quarterly results
Recent quarterly results
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.